{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T21:28:54Z","timestamp":1786742934581,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04243-5","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T11:54:08Z","timestamp":1763726048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early trajectory of inflammatory cytokines following tarlatamab administration in three advanced SCLC patients"],"prefix":"10.1007","volume":"74","author":[{"given":"Takuma","family":"Imakita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Oi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminobu","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"1","key":"4243_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J (2021) Small-cell lung cancer. Nat Rev Dis Primers 7(1):3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"4243_CR2","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/jco.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV et al (2023) Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. JCO 41(16):2893\u20132903. https:\/\/doi.org\/10.1200\/jco.22.02823","journal-title":"JCO"},{"issue":"22","key":"4243_CR3","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/nejmoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E et al (2023) Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 389(22):2063\u20132075. https:\/\/doi.org\/10.1056\/nejmoa2307980","journal-title":"N Engl J Med"},{"issue":"2","key":"4243_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"4243_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"issue":"6","key":"4243_CR6","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.surg.2014.02.006","volume":"155","author":"I Roy","year":"2014","unstructured":"Roy I, Evans DB, Dwinell MB (2014) Chemokines and chemokine receptors: update on utility and challenges for the clinician. Surgery 155(6):961\u2013973. https:\/\/doi.org\/10.1016\/j.surg.2014.02.006","journal-title":"Surgery"},{"issue":"7","key":"4243_CR7","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.4049\/jimmunol.168.7.3195","volume":"168","author":"JH Dufour","year":"2002","unstructured":"Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD (2002) IFN-\u03b3-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168(7):3195\u20133204. https:\/\/doi.org\/10.4049\/jimmunol.168.7.3195","journal-title":"J Immunol"},{"issue":"6","key":"4243_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley SR, Schooley K, Smolak PJ et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3(6):673\u2013682. https:\/\/doi.org\/10.1016\/1074-7613(95)90057-8","journal-title":"Immunity"},{"issue":"6","key":"4243_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.cd-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664\u2013679. https:\/\/doi.org\/10.1158\/2159-8290.cd-16-0040","journal-title":"Cancer Discov"},{"issue":"4","key":"4243_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.annonc.2024.12.004","volume":"36","author":"D Daoudlarian","year":"2025","unstructured":"Daoudlarian D, Segot A, Latifyan S et al (2025) Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy. Ann Oncol 36(4):444\u2013459. https:\/\/doi.org\/10.1016\/j.annonc.2024.12.004","journal-title":"Ann Oncol"},{"issue":"2","key":"4243_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/s1471-4906(00)01812-3","volume":"22","author":"V Appay","year":"2001","unstructured":"Appay V, Rowland-Jones SL (2001) RANTES: a versatile and controversial chemokine. Trends Immunol 22(2):83\u201387. https:\/\/doi.org\/10.1016\/s1471-4906(00)01812-3","journal-title":"Trends Immunol"},{"issue":"5","key":"4243_CR12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1158\/0008-5472.can-11-2493","volume":"72","author":"LY Chang","year":"2012","unstructured":"Chang LY, Lin YC, Mahalingam J et al (2012) Tumor-derived chemokine CCL5 enhances TGF-\u03b2\u2013mediated killing of CD8+ T cells in colon cancer by T-regulatory cells. Cancer Res 72(5):1092\u20131102. https:\/\/doi.org\/10.1158\/0008-5472.can-11-2493","journal-title":"Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04243-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04243-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04243-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:45:16Z","timestamp":1764600316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04243-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":12,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4243"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04243-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was conducted in accordance with the ethical standards of our institution and with the 1964 Declaration of Helsinki and its later amendments. As per our institutional policy, case series involving fewer than 10 patients do not require formal review by the ethics committee. Written informed consent was obtained from all three patients for treatment and inclusion in this report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"382"}}